ライフサイエンスコーパス: IVF

1 IVF being a medical procedure that aims at manipulating

2 IVF patients had both severely abnormal and normal areas

3 IVF placentae, however, displayed hypomethylation of imp

4 IVF procedure is divided into four stages: Superovulatio

5 IVF sensitivity, CS, and VA were not associated with hom

6 IVF sensitivity, CS, and VA were not associated with tot

7 IVF with PGD is a viable option for couples who wish to

8 en 1980 and 1995 (non-IVF group) from all 12 IVF clinics in the Netherlands.

9 FINDINGS: We assessed 124,148 IVF cycles overall, which yielded 33,514 livebirths.

10 had a history of VF and included 21 HCM, 17 IVF, 13 long-QT syndrome (LQTS), 5 dilated cardiomyopath

11 Among 137 women undergoing 180 IVF cycles, urinary BPA concentrations had a geometric m

12 From the 1880s, IVF began to be administered perioperatively to compensa

13 started IVF treatment between 1983 and 1995 (IVF group) and 5950 women starting other fertility treat

14 nt in the Netherlands between 1980 and 1995, IVF treatment compared with non-IVF treatment was not as

15 les (HR, 0.55 [95% CI, 0.39-0.77]) vs 1 to 2 IVF cycles and after poor response to the first IVF cycl

16 Couples (n = 218) underwent 195 IUI and 211 IVF cycles.

17 udy of 156,947 UK women who received 257,398 IVF ovarian stimulation cycles between 2003 and 2010 and

18 Of 30 embryos tested in 4 IVF attempts, 6 were homozygous affected and 24 were una

19 born after an IVF procedure and comparing 5 IVF procedures used in Sweden vs IVF without ICSI with f

20 +/- 4.2 years at enrollment contributed 774 IVF cycles.

21 apy was delivered in 23 patients (29%) of 78 IVF patients with an implantable cardioverter-defibrilla

22 After IVF, all resultant embryos were cryopreserved to preserv

23 The likelihood of a twin birth after IVF rose with increased concentrations of plasma folate

24 n increase in the number of twins born after IVF.

25 tively related with embryo development after IVF.

26 ere less likely to produce a livebirth after IVF (0.24, 0.08-0.71; p=0.003) or to have had a previous

27 the hysteroscopy group had a livebirth after IVF compared with 102 (29%) women in the control group (

28 crotubules to translocate mitochondria after IVF and SCNT in porcine oocytes.

29 imited information on neurodevelopment after IVF exists, especially after the first year of life.

30 The hazard ratio for recurrence after IVF was 0.56 (95% CI, 0.17 to 1.9), and the survival was

31 f mature eggs reached the 2-cell stage after IVF in animals receiving a 3 and 5 days ZDD, respectivel

32 which includes data on more than 95% of all IVF cycles performed in the United States.

33 ase in long-term risk of breast cancer among IVF-treated women.

34 Breast cancer risk among IVF-treated women was also not significantly different f

35 rine surgery (aOR 3.40, 95%CI 1.30-8.91), an IVF pregnancy (aOR 32.13, 95%CI 2.03-509.23) and placent

36 conceived offspring with those born after an IVF procedure and comparing 5 IVF procedures used in Swe

37 one an IVF cycle with her own oocytes and an IVF cycle using donor oocytes from a known donor without

38 She has already undergone an IVF cycle with her own oocytes and an IVF cycle using do

39 sociations were observed between DDT/DDE and IVF outcomes or between HCB and chemical pregnancy or sp

40 glaucoma and subjects in whom better-eye and IVF MD differed by >/= 2 dB.

41 ompare the relative impact of better-eye and IVF MD on driving habits, mobility, self-reported vision

42 The median difference between better-eye and IVF MD was 0.41 dB (interquartile range [IQR], -0.21 to

43 Differences between better-eye and IVF MD were calculated for SEE and clinic-based subjects

44 field testing was performed in each eye, and IVF MD was calculated.

45 rmine temporal trends in the use of ICSI and IVF in the United States, and we examined differences in

46 ocyst tcRNA isolated from individual IVO and IVF produced embryos for miR-18a, -21, and -24.

47 ing early embryonic development from IVO and IVF sources are required to further examine and evaluate

48 relation between serum pesticide levels and IVF outcomes.

49 erent from each other; however, the SCNT and IVF blastocysts displayed surprisingly similar gene expr

50 d mortality rates in the CLEAR III study and IVF represents a safe and effective strategy to hasten c

51 n age of 59.1 years (range, 19-86 years) and IVF mean deviation (MD) of -4.84 dB (range, -27.56 to 2.

52 ome assessment (n = 174) was 71.1 years, and IVF sensitivity ranged from 5.6 to 33.4 dB (mean = 27.2

53 rameters of egg quality for human and animal IVF, as well as improving egg activation protocols for s

54 0.9% NaCl is the most appropriate IVF for the majority of hospitalized children.

55 uals at risk, because except for arrhythmia, IVF does not manifest with identifiable clinical abnorma

56 specific uterine cavity abnormalities before IVF is warranted.

57 Outpatient hysteroscopy before IVF in women with a normal ultrasound of the uterine cav

58 , cancer recurrence rate was similar between IVF and control patients (three of 29 v three of 31 pati

59 mprehensive transcriptome database of bovine IVF and SCNT blastocysts to date.

60 s, had their chance of fathering children by IVF or ICSI reduced by nearly two-thirds.

61 nfants born, 30,959 (1.2%) were conceived by IVF and were followed up for a mean 10 (SD, 6) years.

62 %) with mental retardation were conceived by IVF.

63 cided with reduced incidence of pregnancy by IVF or ICSI, identifying SPTRX3 as a candidate biomarker

64 on analysis detected methylated changes in C-IVF, but not in Natur-IVF, at genes whose methylation co

65 ur-IVF embryos were of higher quality than C-IVF in terms of cell number and hatching ability.

66 sts were produced in vitro either without (C-IVF) or in the presence of natural reproductive fluids (

67 al adoption-at-birth study), and the Cardiff IVF (In Vitro Fertilization) Study (an adoption-at-conce

68 r fluid tonicity with admixtures of clinical IVFs affects sRBC biomechanical properties by leveraging

69 Compared with spontaneous conception, IVF treatment overall was not associated with autistic d

70 cles; reproductive outcomes for conventional IVF and ICSI cycles during 2008-2012, stratified by the

71 RR, 0.93; 95% CI, 0.91-0.95) vs conventional IVF.

72 ltiple birth rate compared with conventional IVF (30.9% vs 34.2%; adjusted relative risk [RR], 0.87;

73 Compared with conventional IVF, ICSI use was not associated with improved postferti

74 the transfer of three or more embryos during IVF (P<0.001) and a 33% decrease in the proportion of tr

75 the transfer of three or more embryos during IVF.

76 The primary limiting factor for effective IVF treatment is successful embryo implantation.

77 (ES cells) from in vitro fertilized embryos (IVF ES cells) represent the 'gold standard', they are al

78 in vitro fertilization embryo-derived ESCs (IVF-ESCs).

79 entration, and the number of previous failed IVF cycles.

80 fects the success of in-vitro fertilisation (IVF) and the rate of resulting twin births so that pregn

81 The success rate of in-vitro fertilisation (IVF) remains low and many women undergo multiple treatme

82 estern countries and in-vitro fertilisation (IVF) services are growing worldwide.

83 echnologies, such as in-vitro fertilisation (IVF) with intracytoplasmic sperm injection (ICSI), can b

84 Following in vitro fertilisation (IVF), only about half of normally fertilised human embry

85 on than conventional in-vitro fertilisation (IVF), which can be successful even when semen characteri

86 nancy outcomes after in-vitro fertilisation (IVF).

87 ing odds ratios with in vitro fertilization (IVF) (165 birth defects, 7.2%) were 1.26 (95% CI, 1.07 t

88 were created during in vitro fertilization (IVF) and are in excess of clinical need.

89 RG mice by combining in vitro fertilization (IVF) and CRISPR/Cas9 technology.

90 en overcome by using in vitro fertilization (IVF) and embryo transfer (ET) techniques.

91 enetic activation or in vitro fertilization (IVF) and tracked their development.

92 ouples who underwent in vitro fertilization (IVF) and/or intrauterine insemination (IUI) cycles in a

93 embryos generated by in vitro fertilization (IVF) but not SCNT.

94 genomic screening in in vitro fertilization (IVF) enables accurate and cost-effective selection of no

95 in women undergoing in vitro fertilization (IVF) from 1994 to 2003.

96 h rates, and data on in vitro fertilization (IVF) from 1997 through 2011 were used to estimate the an

97 oocyte donation for in vitro fertilization (IVF) has increased in the United States, but little info

98 oncepti generated by in vitro fertilization (IVF) in two different genetic backgrounds.

99 safety of performing in vitro fertilization (IVF) in women with breast cancer is unknown.

100 in vitro fertilization (IVF) is one of the most highly pursued assisted reproduc

101 In vitro fertilization (IVF) is the most widely used technique in assisted repro

102 ve birth with repeat in vitro fertilization (IVF) is unclear, yet treatment is commonly limited to 3

103 ) couples treated by in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

104 ate metabolites with in vitro fertilization (IVF) outcomes, accounting for multiple IVF cycles per wo

105 arginine (R72) among in vitro fertilization (IVF) patients.

106 diagnosis (PGD) and in vitro fertilization (IVF) performed for the prevention of genetic prion disea

107 matozoa were used in in vitro fertilization (IVF) studies, and when followed by embryo transfer, >/=

108 rus partially rescue in vitro fertilization (IVF) that failed with epididymal spermatozoa alone.

109 n embryo produced by in vitro fertilization (IVF) that was unaffected by FA and was HLA-identical to

110 developed as part of in vitro fertilization (IVF) to treat male-factor infertility.

111 ites and outcomes of in vitro fertilization (IVF) treatment among couples recruited from an academic

112 Outcomes of in vitro fertilization (IVF) treatment are traditionally reported as pregnancies

113 st cancer risk after in vitro fertilization (IVF) treatment were inconclusive due to limited follow-u

114 Nearly 75% of in vitro fertilization (IVF) treatments do not result in live births and patient

115 ants were born after in vitro fertilization (IVF) treatments.

116 is about to undergo in vitro fertilization (IVF) using donor oocytes from an anonymous donor.

117 oocyte retrieval for in vitro fertilization (IVF) with a positive home pregnancy test, abdominal dist

118 n semen was used for in vitro fertilization (IVF), 10% of embryos were transgenic.

119 Before 8 h of in vitro fertilization (IVF), a mechanism exists that inhibits the association o

120 rm injection (ICSI), in vitro fertilization (IVF), sperm removal, reinjection of the withdrawn sperm,

121 and women undergoing in vitro fertilization (IVF), we consider it an ovarian toxicant.

122 set of zygotes from in vitro fertilization (IVF), we find that success in progression to the blastoc

123 (ICSI) and standard in vitro fertilization (IVF), we found that Ca(2+) influx was not required to in

124 who were undergoing in vitro fertilization (IVF).

125 it over conventional in vitro fertilization (IVF).

126 ong women undergoing in vitro fertilization (IVF).

127 ryos created through in vitro fertilization (IVF).

128 patients undergoing in vitro fertilization (IVF).

129 child as a result of in vitro fertilization (IVF).

130 roved the outcome of in vitro fertilization (IVF).

131 clei stage following in vitro fertilization (IVF).

132 sion analysis of bovine in vitro fertilized (IVF) and SCNT blastocysts as well as respective donor ce

133 etic diagnosis (PGD) of in vitro fertilized (IVF) embryos do not detect de novo single-nucleotide and

134 tute the sperm aster in in vitro-fertilized (IVF) oocytes or originate from the donor cell centrosome

135 Idiopathic ventricular fibrillation (IVF) is a rare cause of sudden cardiac arrest.

136 ly with idiopathic ventricular fibrillation (IVF) manifesting in childhood and adolescence.

137 treatment by intraventricular fibrinolysis (IVF) was recently linked to reduced mortality rates in t

138 egression analysis, the MD of the full-field IVF showed positive associations with near activities (b

139 Binocular integrated visual fields (IVFs) using a best location method were constructed for

140 by using binocular integrated visual fields (IVFs).

141 cycles and after poor response to the first IVF cycle (HR, 0.77 [95% CI, 0.61-0.96] for <4 vs >/=4 c

142 vance to modern practice.Intravenous fluids (IVF) first gained therapeutic importance in the treatmen

143 Clinical intravenous fluids (IVFs) of various tonicities are often used during treatm

144 rinciples of prescribing intravenous fluids (IVFs) to the acutely ill child and of adjusting sodium c

145 d with fertilization or live birth following IVF.

146 oscopy improves the livebirth rate following IVF treatment in women with recurrent failure of implant

147 State-mandated health insurance coverage for IVF services is associated with greater use of ICSI for

148 Gene discovery for IVF is important as it enables the identification of ind

149 e year when clinical practice guidelines for IVF were developed with an aim toward reducing the incid

150 ween surgery and chemotherapy was longer for IVF patients (45.08 v 33.46 days; P < .01).

151 otentially improve greatly the prospects for IVF treatment.

152 Information on ovarian stimulation for IVF, other fertility treatments, and potential confounde

153 Of the 1,395,634 fresh IVF cycles from 1996 through 2012, 908,767 (65.1%) used

154 Among fresh IVF cycles in the United States, ICSI use increased from

155 trospective cohort study using data on fresh IVF and ICSI cycles reported to the US National Assisted

156 nt-ESC counterparts than those derived from IVF-ESCs.

157 Inferior hemifield IVF impacted vision-specific role difficulties and gener

158 .001) while the MD of the inferior hemifield IVF was associated with general vision (beta = 0.04; R2

159 tionnaire and superior or inferior hemifield IVF was determined using multivariable linear regression

160 showed that the MD of the superior hemifield IVF was associated only with near activities (beta = 0.0

161 Superior hemifield IVF was strongly associated with difficulty with near ac

162 Her IVF cycle included the usual cocktail for gonadotropin s

163 ng method, genetically matched sets of human IVF ES cells, iPS cells and nuclear transfer ES cells (N

164 historic approach of administering hypotonic IVFs results in a high incidence of hospital-acquired hy

165 l reconstruction versus sperm retrieval/ICSI/IVF are neither randomized nor homogenous.

166 Mortality rate was 9% in IVF patients (8/85).

167 ecurrence rate of ventricular arrhythmias in IVF patients is high.

168 h follow-up and reassessment of diagnosis in IVF patients.

169 f SNPs in p63 and p73 genes were enriched in IVF patients.

170 es p53 levels in cells, are also enriched in IVF patients.

171 ity is a major cause of pregnancy failure in IVF programs.

172 ough numerous advancements have been made in IVF procedures, little attention has been given to modif

173 oth oocyte ranking and embryo preferences in IVF applications.

174 Nevertheless, implantation rates in IVF programs remain low despite the transfer of apparent

175 Breast cancer risk in IVF-treated women was not significantly different from t

176 clear area was lower in SCNT oocytes than in IVF oocytes.

177 Secondary endpoints included IVF- and LD-related safety, such as bleeding or infectio

178 soldiers from the Korean War receiving large IVF infusions and surviving, dictated the surgical pract

179 with Tam-IVF, both TamFSH-IVF and Letrozole-IVF patients had greater numbers of follicles (2 +/- 0.3

180 zole 5 mg in combination with FSH (Letrozole-IVF).

181 moxifen (TamFSH-IVF) or letrozole (Letrozole-IVF) results in higher embryo yield compared with Tam-IV

182 radiol (E2) levels were lower with Letrozole-IVF and Tam-IVF compared with TamFSH-IVF.

183 g, dictated the surgical practice of liberal IVF administration until very recently.Newer work in flu

184 Unlike better-eye MD, IVF measurements require extra software/calculation.

185 ntribution, we generated a prediction model, IVF(BT), that was superior to the age-based control by p

186 ntly lower for those who underwent 7 or more IVF cycles (HR, 0.55 [95% CI, 0.39-0.77]) vs 1 to 2 IVF

187 e, accounting for correlation among multiple IVF cycles in the same woman using generalized estimatin

188 tion (IVF) outcomes, accounting for multiple IVF cycles per woman.

189 s with IVF outcomes, accounting for multiple IVF cycles per woman.

190 Natur-IVF embryos were of higher quality than C-IVF in terms o

191 esence of natural reproductive fluids (Natur-IVF).

192 by culture, with fewer aberrations in Natur-IVF embryos.

193 ethylated changes in C-IVF, but not in Natur-IVF, at genes whose methylation could be critical, such

194 d DNA methylation analyses showed that Natur-IVF embryos have expression and methylation patterns clo

195 tility treatments between 1980 and 1995 (non-IVF group) from all 12 IVF clinics in the Netherlands.

196 oup (0.92 [95% CI, 0.73-1.15]) or in the non-IVF group (1.03 [95% CI, 0.82-1.29]).

197 ardized incidence ratios [SIRs]) and the non-IVF group (hazard ratios [HRs]).

198 CI, 0.93-1.09]) and from the risk in the non-IVF group (HR, 1.01 [95% CI, 0.86-1.19]).

199 3.0% for the IVF group and 2.9% for the non-IVF group (P = .85).

200 for the IVF group and 55.3 years for the non-IVF group.

201 ths that were attributable to IVF and to non-IVF fertility treatments, after adjustment for maternal

202 80 and 1995, IVF treatment compared with non-IVF treatment was not associated with increased risk of

203 ndergoing their first fresh-embryo, nondonor IVF cycle between 2000 and 2005 at one large center.

204 tricles) or a combined treatment approach of IVF and-upon clot clearance of third and fourth ventricl

205 ompared to IVF alone, a combined approach of IVF plus LD treatment is feasible and safe and significa

206 endency for a combined treatment approach of IVF plus lumbar drains (LDs).

207 hasized the importance of the composition of IVF and laid the foundations for the balanced solutions

208 e month before starting a treatment cycle of IVF (with or without intracytoplasmic sperm injection).

209 After her parents underwent 5 cycles of IVF with intrauterine transfer of 7 embryos over a span

210 cutive patients with an initial diagnosis of IVF were analyzed (age at index event 40.4 years, 60% ma

211 Further, we evaluated the effects of IVF culture on the expression of specific miRNA at the b

212 The evolution of IVF has raised concerns of increased cancer risks, inclu

213 After 10 h of IVF the inhibition of G9a activity depends on yet unknow

214 sms of transfer take place between 8-10 h of IVF, and the novel protein failed to inhibit G9a activit

215 The introduction of IVF and intracytoplasmic sperm injection revolutionized

216 port the efficacy of extending the number of IVF cycles beyond 3 or 4.

217 age at baseline, 32.8 years; mean number of IVF cycles, 3.6), 839 cases of invasive breast cancer an

218 ta are available on the long-term outcome of IVF patients.

219 The percentage of IVF cycles with the use of ICSI also increased dramatica

220 ics and fresh-embryo cycles and the rates of IVF-related pregnancies and live births increased.

221 The science of IVF has evolved significantly in the last several years,

222 NT ES cells corresponded closely to those of IVF ES cells, whereas iPS cells differed and retained re

223 rospective clinical study addressing optimal IVF management during VOE in SCD.

224 min after entry, and by 120 min post-ICSI or IVF, sperm were unable to induce oscillations.

225 ion induction, intrauterine insemination, or IVF did not differ significantly between the groups.

226 ion induction, intrauterine insemination, or IVF.

227 be replicated and further validated in other IVF clinics.

228 re traditionally reported as pregnancies per IVF cycle.

229 Live-birth rate per IVF cycle and the cumulative live-birth rates across all

230 5) who provided one or two urine samples per IVF cycle.

231 0.9% NaCl is the preferred IVF for the vast majority of hospitalized children.

232 For specific procedures, IVF with ICSI for paternal infertility was associated wi

233 lation in fetal brain or liver samples, rare IVF concepti displayed very low methylation and abnormal

234 standard treatment (control group receiving IVF consisting of 1mg of recombinant human tissue plasmi

235 n overall 97 patients, 45 patients receiving IVF plus LD versus 42 with IVF only.

236 majority of hospitalized children requiring IVFs are at risk for developing hyponatremia from numero

237 specific instances in which sperm retrieval/IVF/ICSI may be a more appropriate treatment modality as

238 We observed decreased success for several IVF outcomes across increasing quartiles of both summed

239 or the purpose of subsequent or simultaneous IVF/intracytoplasmic sperm injection.

240 The cohort included 19,158 women who started IVF treatment between 1983 and 1995 (IVF group) and 5950

241 d efficacy and safety of a combined strategy-IVF plus LD versus IVF alone-on shunt dependency in pati

242 t patients who did not return for subsequent IVF cycles would have the same chance of a pregnancy res

243 In women likely to have a successful IVF pregnancy, high folate status increases the likeliho

244 les with either tamoxifen 60 mg/d alone (Tam-IVF) or in combination with low-dose follicle-stimulatin

245 levels were lower with Letrozole-IVF and Tam-IVF compared with TamFSH-IVF.

246 Compared with Tam-IVF, both TamFSH-IVF and Letrozole-IVF patients had grea

247 lts in higher embryo yield compared with Tam-IVF.

248 Compared with Tam-IVF, both TamFSH-IVF and Letrozole-IVF patients had greater numbers of fo

249 ow-dose follicle-stimulating hormone (TamFSH-IVF) or letrozole 5 mg in combination with FSH (Letrozol

250 ation of low-dose FSH with tamoxifen (TamFSH-IVF) or letrozole (Letrozole-IVF) results in higher embr

251 trozole-IVF and Tam-IVF compared with TamFSH-IVF.

252 Our results indicate that IVF may largely overcome infertility in younger women, b

253 The IVF MD rarely differs from better-eye MD, and similar as

254 The IVF was further stratified by VF location (superior vs i

255 IVM restored histone H3K4me3 and doubled the IVF success rate from 17% to 43% in oocytes from zinc de

256 Embryos that are discarded during the IVF procedure because of poor morphology and a low likel

257 of breast cancer at age 55 were 3.0% for the IVF group and 2.9% for the non-IVF group (P = .85).

258 e at end of follow-up was 53.8 years for the IVF group and 55.3 years for the non-IVF group.

259 ghrelin, number of oocytes retrieved in the IVF cycle, and pregnancy rate were determined.

260 18 +/- 0.87, respectively; P = 0.039) in the IVF cycle.

261 er time since treatment (>/=20 years) in the IVF group (0.92 [95% CI, 0.73-1.15]) or in the non-IVF g

262 Breast cancer risk in the IVF group was compared with risks in the general populat

263 Overall, 42% (n = 75) of the IVF cycles resulted in implantation failure.

264 ior compared with the inferior region of the IVF ranged from 2.1 (95% confidence interval, 2.1-2.4) t

265 the sensitivity values (in decibels) of the IVFs to determine common defect patterns in an automated

266 Furthermore, embryos created through IVF are currently evaluated for developmental potential

267 of fertilized embryos were produced through IVF, and a high rate of Fah gene targeting was achieved

268 plet and higher-order births attributable to IVF (P<0.001).

269 of multiple births that were attributable to IVF and to non-IVF fertility treatments, after adjustmen

270 in patients with severe IVH, as compared to IVF alone, a combined approach of IVF plus LD treatment

271 us on perioperative fluid therapy has led to IVF administration being guided by physiological princip

272 cytes were matured in vitro and subjected to IVF in the presence of rAC.

273 Five novel tripeptides, IVF, LLF, LNF, LSW and LEF, with predicted IC50 values l

274 controls (n = 31) who elected not to undergo IVF.

275 Among women in the United Kingdom undergoing IVF, the cumulative prognosis-adjusted live-birth rate a

276 spective cohort study among women undergoing IVF at the Massachusetts General Hospital Fertility Cent

277 h failed implantation among women undergoing IVF.

278 We identified a mutation in CALM1 underlying IVF manifesting in childhood and adolescence.

279 vity and history of two to four unsuccessful IVF cycles.

280 uterine cavity and a history of unsuccessful IVF treatment cycles does not improve the livebirth rate

281 treatment of women who fail to conceive upon IVF and suggests new avenues for developing intervention

282 Using IVF to investigate human reproduction and pregnancy outc

283 the first successful transplantation, using IVF and PGD, of HSCs from a donor selected on the basis

284 ty of a combined strategy-IVF plus LD versus IVF alone-on shunt dependency in patients with ICH and s

285 sk of VF and in patients with idiopathic VF (IVF).

286 obtained to calculate average integrated VF (IVF) sensitivity.

287 were transformed to binocular integrated VF (IVF).

288 ment and between in vivo (IVO) and in vitro (IVF) produced embryos.

289 comparing 5 IVF procedures used in Sweden vs IVF without ICSI with fresh embryo transfer, the most co

290 The exposure of interest was IVF, categorized according to whether intracytoplasmic s

291 g, and there is no consensus regarding which IVFs to use during VOE.

292 atients receiving IVF plus LD versus 42 with IVF only.

293 reased risk of birth defects associated with IVF was no longer significant after adjustment for paren

294 he increase in absolute risk associated with IVF was small.

295 Compared with IVF without ICSI with fresh embryo transfer, there were

296 isorder and mental retardation compared with IVF without ICSI.

297 fth of the patients initially diagnosed with IVF reveal a specific diagnosis during long-term follow-

298 osted tree model, IVFBT, by training it with IVF outcomes data from 1,676 first cycles (C1s) from 200

299 the association of the PFR metabolites with IVF outcomes, accounting for multiple IVF cycles per wom

300 w altering extracellular fluid tonicity with IVFs affects sRBC biomechanics in the microcirculation,